Laddar...
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma
While advanced surgical techniques, radiation therapy and chemotherapeutic regimens provide a tangible benefit for patients with glioblastoma (GBM), the average survival from the time of diagnosis remains less than 15 months. Current therapy for GBM is limited by the nonspecific nature of treatment,...
Sparad:
| Huvudupphovsmän: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4034273/ https://ncbi.nlm.nih.gov/pubmed/23927666 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17512433.2013.811806 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|